Is CASI Pharmaceuticals, Inc. overvalued or undervalued?

As of 12 November 2019, the valuation grade for CASI Pharmaceuticals, Inc. moved from does not qualify to risky. The company is currently assessed as overvalued given its negative financial metrics and performance indicators. Key ratios include a Price to Book Value of -3.67, an EV to EBIT of -0.88, and an EV to Sales of 1.13, which highlight significant financial distress.
In comparison to peers, CASI Pharmaceuticals has a P/E ratio of -0.5556, while Assembly Biosciences, Inc. also rated as risky, has a P/E of -3.2679. Additionally, Fortress Biotech, Inc. has a P/E of -0.5040, indicating that CASI is not alone in its struggles but still reflects a concerning valuation relative to its industry. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -56.54% compared to the S&P 500's 2.44%, reinforcing the view that CASI Pharmaceuticals is overvalued.